Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 28, 2026
Business Overview: Henry Schein is a global solutions company for healthcare professionals, primarily serving office-based dental and medical practitioners. The company operates through three reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $3,368 million | $3,168 million |
| Gross Profit | $1,070 million | $1,000 million |
| Gross Margin | 31.8% | 31.6% |
| Operating Income | $182 million | $175 million |
| Net Income (Total) | $112 million | $113 million |
| Net Income Attributable to Henry Schein | $107 million | $110 million |
| Diluted EPS | $0.92 | $0.88 |
| Operating Cash Flow | ($97) million | $37 million |
| Total Debt | $3,408 million | $3,107 million |
| Cash and Cash Equivalents | $138 million | $127 million |
| Working Capital | $1,199 million | $1,236 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.3% year-over-year, driven by 2.5% internal growth, 0.7% acquisition growth, and a 3.1% positive foreign exchange impact.
- Segment Performance:
- Global Distribution: Sales up 6.1% (Dental up 9.0%, Medical up 1.7%).
- Global Specialty Products: Sales up 8.1% due to growth in value implant and biomaterial businesses.
- Global Technology: Sales up 7.0% driven by adoption of cloud-based practice management solutions.
- Profitability: Operating income increased 4.0% to $182 million. Gross margin expanded slightly to 31.8% due to favorable business mix and higher margins in Distribution and Technology segments.
- Restructuring Costs: Restructuring and related costs decreased significantly to $12 million from $25 million in the prior year, primarily due to lower severance and exit costs.
- Cash Flow: Operating cash flow turned negative ($97 million used) compared to $37 million provided in the prior year, primarily due to working capital changes (increases in accounts receivable and decreases in accounts payable).
- Debt: Total debt increased by $301 million to $3.408 billion, driven by increased borrowings under bank credit lines and private placement facilities.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted the successful integration of acquisitions and the "One Schein" initiative to unify go-to-market approaches. The company expects the 2024 restructuring plan to continue through the end of 2027, though specific future charge estimates are not yet determined.
- Leadership Transition: Frederick M. Lowery was appointed CEO effective March 2, 2026, succeeding Stanley M. Bergman, who retired as CEO and continues as Chairman Emeritus.
- Strategic Partnership: The company maintains a strategic partnership with KKR, which holds a significant equity stake and board representation. KKR exercised an extension election for its board designees.
- Risks and Contingencies:
- Trade Policy: Ongoing volatility regarding U.S. tariffs and retaliatory measures creates uncertainty for global trade, though the impact on Q1 2026 results was not material.
- Regulatory Environment: The company faces evolving regulations including the FDA's Quality Management System Regulation (QMSR), EU AI Regulation, and the EU Directive on Combating Corruption.
- Legal Proceedings: Opioid-related litigation has been settled for immaterial amounts. Other pending legal matters are not expected to have a material adverse effect.
- Capital Allocation: The company continues to pursue share repurchases, with $655 million remaining available under current authorizations. An accelerated share repurchase program of $250 million was completed in 2025.
Investor Verification Checklist
- Working Capital Dynamics: Verify the drivers behind the $134 million swing in operating cash flow, specifically the increase in accounts receivable days sales outstanding (45.7 days vs. 44.1 days) and the decrease in inventory turns (4.6 vs. 4.8).
- Debt Servicing: Review the impact of rising interest rates on the $3.4 billion debt load, noting the weighted average interest rates on private placement facilities (3.99%) and term loans (5.60% effective rate).
- Restructuring Progress: Monitor the execution of the 2024 restructuring plan and the timing of future charges expected through 2027.
- Acquisition Integration: Assess the integration of recent acquisitions in the Global Specialty Products and Global Distribution segments, including the $11 million gain on remeasurement of a previously held equity investment.
- Regulatory Compliance: Track the implementation costs and operational impacts of new regulations such as the FDA QMSR and EU AI Act.